TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05798923: LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Sponsor: IRulya Therapeutics Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 85 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$1,759,600

Rescue Site Savings

+$1,162,000

Unlock Full NCT05798923 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05798923 Rescue Dossier →